Sareum Holdings PLC
("Sareum" or the "Company")
Notice of AGM, Annual Report and Accounts
Cambridge, UK, 21 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's Annual General Meeting ("AGM") will be held at 10.00am on 14 December 2023 at 85 Gresham Street, London EC2V 7NQ.
In order to allow shareholders to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company ("IMC") platform. Shareholders who wish to follow the AGM online should register for the event in advance by using the following link: www.investormeetcompany.com/sareum-holdings-plc/register-investor.
Shareholders are invited to submit questions for the Board to consider in the Q&A session to be held immediately after the AGM. Questions can be pre submitted via the IMC Platform up until 9.00am the day before the meeting and can be submitted at any time during the AGM itself. Shareholders are reminded that following the AGM online will not constitute attendance at the AGM and therefore will not be able to vote on the day.
Shareholders intending to vote should do so via the shareholder portal at www.signalshares.com where details of the procedure are shown. Alternatively, shareholders may request a paper form of proxy from our registrars, Link Group.
The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2023, will be posted today to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website: www.sareum.com
-Ends-
For further information, please contact:
| Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations
|
01223 497700 ir@sareum.co.uk |
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
| Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
| Hybridan LLP (Joint Corporate Broker) Claire Noyce
ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3764 2341
020 3709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.